Language:

Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis

Drug design, development and therapy, 2020-01, Vol.14, p.157-165 [Peer Reviewed Journal]

2020 Yang et al. ;COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Yang et al. 2020 Yang et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/dddt.s213968 ;PMID: 32021100

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis
Author: Yang, Han ; Li, Nan ; Zhou, Youlian ; Xiao, Zhilan ; Tian, Haoming ; Hu, Ming ; Li, Sheyu
Subjects: Analysis ; Anticholesteremic agents ; Anticholesteremic Agents - administration & dosage ; Anticholesteremic Agents - economics ; Anticholesteremic Agents - therapeutic use ; Antilipemic agents ; Cardiovascular agents ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - economics ; China ; Cholesterol ; Computer simulation ; Cost analysis ; Cost benefit analysis ; cost-effectiveness analysis ; Discount rates ; Diseases ; Dosage ; Dosage and administration ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Economic aspects ; Electronic health records ; Electronic medical records ; Electronic records ; Ezetimibe ; Ezetimibe - administration & dosage ; Ezetimibe - economics ; Ezetimibe - therapeutic use ; Gross domestic product ; Humans ; lipid-lowering treatment ; Low density lipoprotein ; Low density lipoproteins ; Markov Chains ; markov model ; Markov processes ; Medical records ; Monte Carlo Method ; Mortality ; Original Research ; Prevention ; Quality-Adjusted Life Years ; Renminbi (China) ; Rosuvastatin ; Rosuvastatin Calcium - administration & dosage ; Rosuvastatin Calcium - economics ; Rosuvastatin Calcium - therapeutic use ; Secondary Prevention ; secondary prevention of cardiovascular diseases ; Sensitivity analysis ; Statins ; Statistical analysis ; Transition probabilities
Is Part Of: Drug design, development and therapy, 2020-01, Vol.14, p.157-165
Description: For patients with inadequate control of cholesterol using moderate-dose statins in the secondary prevention of cardiovascular diseases (CVD), either doubling the dose of statins or adding ezetimibe should be considered. The cost-effectiveness of them is unknown in the Chinese context. The aim of this study is to compare the cost and effectiveness of the two regimens, and estimate the incremental cost-effectiveness ratio (ICER). A Markov model of five health statuses were used to estimate long-term costs and quality-adjusted life-years (QALYs) of the two treatment regimens from the healthcare perspective. The effectiveness data used to calculate the transition probability was based on a previously published randomized trial. The utility data was gathered from literature and the costs were gathered from the electronic medical record system of West China Hospital in Chinese Yuan (CNY) in 2017 price. One-way sensitivity analysis and probabilistic sensitivity analysis were conducted. The ICER for ezetimibe plus moderate-dose rosuvastatin was 47,102.99 CNY per QALY for 20 years simulation, which did not reach the threshold of per capita gross domestic product (GDP) of 59,660 CNY per QALY in 2017 in China. Non-CVD-related mortality and CVD-related mortality contributed most to the ICER. Adding ezetimibe to the moderate-dose statin in secondary prevention for CVD is cost-effective, compared with the high-dose statin in the Chinese context whose low-density lipoprotein cholesterol (LDL-c) was not inadequately controlled by moderate-dose statin alone.
Publisher: New Zealand: Dove Medical Press Limited
Language: English
Identifier: ISSN: 1177-8881
EISSN: 1177-8881
DOI: 10.2147/dddt.s213968
PMID: 32021100
Source: Open Access: DOAJ Directory of Open Access Journals
Open Access: PubMed Central
Geneva Foundation Free Medical Journals at publisher websites
AUTh Library subscriptions: ProQuest Central
DOVE Medical Press OA Journals
MEDLINE
ROAD: Directory of Open Access Scholarly Resources

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis

Searching Remote Databases, Please Wait